In this task, you're given a paragraph and title from the research paper. Your task is to classify whether the given title is suitable or not for the research paper based on the given paragraph. Return "True" if title is proper according to paragraph else "False".
--------
Question: Paragraph: Human cytomegalovirus (HCMV) is a ubiquitous betaherpesvirus that frequently causes morbidity and mortality in individuals with insufficient immunity, such as transplant recipients, AIDS patients, and congenitally infected newborns. Several antiviral drugs are approved to treat HCMV infections. However, resistant HCMV mutants can arise in patients receiving long-term therapy. Additionally, side effects and the risk to cause birth defects limit the use of currently approved antivirals against HCMV. Therefore, the identification of new drug targets is of clinical relevance. Recent work identified DNA-damage binding protein 1 (DDB1) and the family of the cellular cullin (Cul) RING ubiquitin (Ub) ligases (CRLs) as host-derived factors that are relevant for the replication of human and mouse cytomegaloviruses. The first-in-class CRL inhibitory compound Pevonedistat (also called MLN4924) is currently under investigation as an anti-tumor drug in several clinical trials. Cytomegaloviruses exploit CRLs to regulate the abundance of viral proteins, and to induce the proteasomal degradation of host restriction factors involved in innate and intrinsic immunity. Accordingly, pharmacological blockade of CRL activity diminishes viral replication in cell culture. In this review, we summarize the current knowledge concerning the relevance of DDB1 and CRLs during cytomegalovirus replication and discuss chances and drawbacks of CRL inhibitory drugs as potential antiviral treatment against HCMV.
Title: Molecular Sciences Cellular Cullin RING Ubiquitin Ligases: Druggable Host Dependency Factors of Cytomegaloviruses

Answer: True

Question: Paragraph: Purpose: COVID-19 has become global threaten. CT acts as an important method of 60 diagnosis. However, human-based interpretation of CT imaging is time consuming. 61 More than that, substantial inter-observer-variation cannot be ignored. We aim at 62 developing a diagnostic tool for artificial intelligence (AI)-based classification of CT 63 images for recognizing COVID-19 and other common infectious diseases of the lung. 64 Experimental Design: In this study, images were retrospectively collected and 65 prospectively analyzed using machine learning. CT scan images of the lung that show 66 or do not show COVID-19 were used to train and validate a classification framework 67 based on convolutional neural network. Five conditions including COVID-19 68 pneumonia, non-COVID-19 viral pneumonia, bacterial pneumonia, pulmonary 69 tuberculosis, and normal lung were evaluated. Training and validation set of images 70 were collected from Wuhan Jin Yin-Tan Hospital whereas test set of images were 71 collected from Zhongshan Hospital Xiamen University and the fifth Hospital of 72 Wuhan. 73 Results: Accuracy, sensitivity, and specificity of the AI framework were reported. For 74 test dataset, accuracies for recognizing normal lung, COVID-19 pneumonia, 75 non-COVID-19 viral pneumonia, bacterial pneumonia, and pulmonary tuberculosis 76 were 99.4%, 98.8%, 98.5%, 98.3%, and 98.6%, respectively. For the test dataset, 77 accuracy, sensitivity, specificity, PPV, and NPV of recognizing COVID-19 were 78 98.8%, 98.2%, 98.9%, 94.5%, and 99.7%, respectively. 79 All rights reserved. No reuse allowed without permission. the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
Title: Deep Learning-Based Recognizing COVID-19 Deep Learning-Based Recognizing COVID-19 and other Common Infectious Diseases of the Lung by Chest CT 2 Scan Images

Answer: False

Question: Paragraph: Broad-spectrum antiviral drugs are urgently needed to treat individuals infected with new and reemerging viruses, or with viruses that have developed resistance to antiviral therapies. Mammalian natural host defense peptides (mNHP) are short, usually cationic, peptides that have direct antimicrobial activity, and which in some instances activate cell-mediated antiviral immune responses. Although mNHP have potent activity in vitro, efficacy trials in vivo of exogenously provided mNHP have been largely disappointing, and no mNHP are currently licensed for human use. Mastoparan is an invertebrate host defense peptide that penetrates lipid bilayers, and we reasoned that a mastoparan analog might interact with the lipid component of virus membranes and thereby reduce infectivity of enveloped viruses. Our objective was to determine whether mastoparan-derived peptide MP7-NH 2 could inactivate viruses of multiple types, and whether it could stimulate cell-mediated antiviral activity. We found that MP7-NH 2 potently inactivated a range of enveloped viruses. Consistent with our proposed mechanism of action, MP7-NH 2 was not efficacious against a non-enveloped virus. Pre-treatment of cells with MP7-NH 2 did not reduce the amount of virus recovered after infection, which suggested that the primary mechanism of action in vitro was direct inactivation of virus by MP7-NH 2 . These results demonstrate for the first time that a mastoparan derivative has broad-spectrum antiviral activity in vitro and suggest that further investigation of the antiviral properties of mastoparan peptides in vivo is warranted.
Title: A mastoparan-derived peptide has broad-spectrum antiviral activity against enveloped viruses

Answer:
True